Olympus Corporation

Olympus Corporation

Consolidated Financial Results for the 3rd Quarter Fiscal 2023

February 10, 2023

Chikashi Takeda
Executive Officer and Chief Financial Officer
Nacho Abia
Executive Officer and Chief Operating Officer
Pierre Boisier
Chief Quality Officer

PLAY LIST

from the beginning

Consolidated Financial Results for the 3rd Quarter and Full-year Forecasts for Fiscal 2023
Disclaimer
Highlights
  • 01. Consolidated Financial Results and Business Review for the 3Q of Fiscal 2023 (FY Ending March 31, 2023)
3Q of Fiscal 2023 (1) Consolidated Financial Results
3Q of Fiscal 2023 (2) Endoscopic Solutions Division (ESD)
3Q of Fiscal 2023 (3) Therapeutic Solutions Division (TSD)
Statement of Financial Position
Consolidated Cash Flows
  • 02. Forecasts for Fiscal 2023
Fiscal 2023 Consolidated Forecasts
Fiscal 2023 Forecasts by Business Segment
FDA Warning Letters and Efforts to Strengthen QARA
@
Appendix
Changes in Reporting Structure
3Q of Fiscal 2023 Factors that Affected Consolidated Operating Profit
3Q of Fiscal 2023 Discontinued Operation (Scientific Solutions Business)
3Q of Fiscal 2023 Results by Segment
Factors that Affected Consolidated Cash Flows
Key Product Catalysts: Endoscopic Solutions Division (As of Feb. 10, 2023)
Key Product Catalysts: Therapeutic Solutions Division (As of Feb. 10, 2023)
Expenditures, etc.
Foreign Exchange and Sensitivity
Q&A
  • Q&A 1
  • Q&A 2
  • Q&A 3
  • Q&A 4
  • Q&A 5
  • Q&A 6
  • Back
  • Next

Download

  • Presentation Materials(PDF 1.7 MB)
  • Tanshin (Financial Results)(PDF 542 KB)
  • Financial Data(PDF 300 KB)
  • Questionnaire Please answer the questionnair
  • Forward-Looking Statements
    System Requirements
GreenPower
link corporate communications